Q1 Earnings Estimate for ADAP Issued By Leerink Partnrs

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a research note issued on Tuesday, March 25th. Leerink Partnrs analyst J. Chang anticipates that the biotechnology company will post earnings of ($0.10) per share for the quarter. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS and FY2026 earnings at ($0.11) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The firm had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million.

ADAP has been the topic of a number of other reports. Guggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research note on Wednesday. Scotiabank reduced their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. Wells Fargo & Company dropped their price objective on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday, March 21st. Finally, StockNews.com started coverage on Adaptimmune Therapeutics in a report on Friday, March 21st. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1.93.

Adaptimmune Therapeutics Stock Down 6.4 %

Shares of NASDAQ ADAP opened at $0.21 on Friday. Adaptimmune Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.55. The firm’s 50-day moving average is $0.51 and its 200-day moving average is $0.67. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $52.71 million, a PE ratio of -0.94 and a beta of 2.52.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 28,526 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of Adaptimmune Therapeutics by 492.0% during the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 58,787 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC grew its position in shares of Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 21,688 shares during the period. Finally, LPL Financial LLC increased its stake in Adaptimmune Therapeutics by 106.5% during the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 94,623 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.